NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with Irish Pharmacist includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

ADVERTISMENT

ADVERTISMENT

Research identifies new therapeutic options for childhood inflammatory bowel disease 

By Irish Pharmacist - 28th Feb 2022

IBD 

Inflammatory bowel disease (IBD) affects approximately 40,000 patients in Ireland, with 25 per cent of these cases first arising during childhood. Globally, the prevalence for IBD is 396 cases per 100,000 persons annually. Symptoms include abdominal pain, persistent diarrhoea, weight loss and fatigue. The exact cause of the disease remains unknown. 

Researchers from the School of Medicine, Trinity College, working closely with paediatric gastroenterologists at CHI-Crumlin, have previously shown that small proteins known as IL-36 cytokines are ‘switched on’ in the inflamed intestines of children with newly-diagnosed IBD. However, it is still not fully understood how IL-36 cytokines drive disease. 

Now, new research from the team addresses this by demonstrating how IL-36 can instruct proinflammatory CD4+ T cells to accumulate in the inflamed intestine and worsen disease. Identifying how these proteins promote disease progression will be invaluable in advancing efforts to target their activity among IBD patients as a new therapeutic option, said the authors. The study was published recently in the journal Mucosal Immunology

IL-36 acts as an instructive signal to drive inflammation in different tissue sites. Its activity is perhaps best characterised in the skin, where it is thought to play an important role in driving chronic inflammation in diseases such as psoriasis. Normally, the activity of IL-36 is tightly regulated in healthy tissues to ensure that inappropriate activity does not result in chronic inflammation. For ill-defined reasons, this regulation appears to be lost in IBD. 

The key finding of the study identifies how IL-36 can cause the accumulation of the damaging CD4+ T cells in the inflamed intestine, where they play a central role in driving the inflammation observed in IBD. These findings build upon the team’s earlier work, which identified that IL-36 cytokines were elevated among children with IBD and were associated with worsening disease outcomes. 

Identifying how these proteins promote disease progression offers fresh insights and will advance efforts to target their activity among IBD patients as a new therapeutic option, they wrote. 

This study is part of a long-standing programme of translational research between Trinity and paediatric gastroenterologists led by Prof Seamus Hussey at the National Children’s Research Centre and CHI Crumlin, which tries to understand the causes of IBD onset during its earliest stages in children/adolescents. 

Prof Patrick Walsh, Associate Professor in Paediatric Immunology, Department Of Clinical Medicine at Trinity’s School of Medicine, said: “These results shed new light on how a potential new therapeutic target can promote the early pathogenesis of IBD. Gaining a deeper understanding of how IBD develops during its earliest stages, in childhood and adolescence, is critically important in efforts to design new and improved treatment options for these patients as they transition to adulthood.” 

The study was supported through funding from the National Children’s Research Centre Crumlin, the Health Research Board, Crohn’s & Colitis Foundation, and the Irish Research Council.

ADVERTISMENT

Latest

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

Latest Issue

Irish Pharmacist July 2024

Irish Pharmacist July 2024

Irish Pharmacist July 2024. Volume 25 | Issue 7 | July 2024. Read the latest issue of Irish Pharmacist here…

Read

OTC Update Spring 2024

Spring 2024 | Issue 1 | Volume 18. Read the latest issue of OTC Update here.

Read

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT

ADVERTISMENT